Connect with us

Health

Cleveland Clinic Performs First-In-World Full Multi-Organ Transplant to Treat Rare Appendix Cancer

Published

on

#USA, August 13, 2022 – Cleveland Clinic has successfully performed a first-in-the-world full multi-organ transplant to treat a patient with a rare form of appendix cancer called pseudomyxoma peritonei (PMP). Upon completion of the lifesaving transplant surgery, the patient received five digestive organs: liver, stomach, pancreas, duodenum, and small intestine.

Anil Vaidya, M.D., Cleveland Clinic’s Intestinal Transplant Program co-director, led the seven-surgeon team that completed the pioneering operation on a 32-year-old man in September 2021.

“The patient had one of the more advanced cases of PMP I have seen,” said Dr. Vaidya. “While about 80% of patients with the condition can be treated with traditional therapies, what do you do with the 20% for whom the traditional therapy isn’t successful? In some cases, the answer may be a multi-organ transplant.”

During the 17-hour operation, surgeons removed the patient’s diseased organs. He then received the following deceased donor’s organs all together and at the same time: liver, stomach, pancreas and duodenum (pancreaticoduodenal complex), spleen, small intestine, and right colon. The donor spleen was initially transplanted to boost the immune protection of the newly transplanted organs and improve blood flow to the pancreas until fully transplanted. The donor right colon was initially transplanted to help protect the new intestine from infection and improve its ability to absorb nutrients.  Both the donor spleen and donor right colon were removed prior to the completion of the transplant after they successfully served to protect the other organs during the operation.

“As far as we know, it is the first time in the world that a full multi-organ transplant, including the liver and four other digestive organs, is performed to treat PMP,” said Dr. Vaidya.

Prior to joining Cleveland Clinic in 2020, Dr. Vaidya performed in England the world’s first modified multi-organ transplant (excluding the liver) to treat a patient with PMP who had exhausted all other management strategies.

PMP is a rare cancer that typically originates as a tumor in the appendix. When the slow-growing tumor ruptures, its jelly-like content spreads to other digestive organs, with additional tumors developing that impair gastrointestinal function. Malnutrition and life-threatening complications ultimately occur.

Following the diagnosis in 2019, the patient began a long odyssey of treatments. He was one of the 20% of patients with PMP for whom the traditional treatments were ineffective. Often, this population of patients is left with few to no treatment options.

The patient was referred to Cleveland Clinic in 2021 in the end stage of his disease. He was receiving hospice care at that time. The patient had stopped working and could no longer eat solid foods. He was receiving nutrients intravenously through total parenteral nutrition (TPN).

“We needed to perform an evaluation to determine if transplantation in his case was safe, feasible and could provide long-term benefits,” said Dr. Vaidya.

Dr. Vaidya completed a thorough assessment of the patient’s case and received approval from Cleveland Clinic’s Intestinal Transplant Selection Committee to proceed. The patient was placed on the national transplant waiting list in July 2021.

“The patient – who needed a liver and four other digestive organs – had started to deteriorate quite rapidly,” said Dr. Vaidya. “It was touch-and-go that he would make it.”

In September 2021, a donor was found, and less than 24 hours later, the patient was undergoing the groundbreaking

surgery. The first three hours were preparatory, in essence removing the diseased abdominal organs. Next, the donor organs were inserted into the abdominal cavity, all the necessary vascular connections were completed and a left-sided ileostomy was created to handle bodily waste and let the body recover from the surgery.

“The operation was well planned and went like clockwork,” said Dr. Vaidya. “The team members knew exactly what they were going to do, and the timing was perfect. It went really well.”

Following the transplant, the patient remained in the hospital for 51 days.  Soon after he was discharged, he returned because he was suffering from a case of graft-versus-host disease, a common occurrence following intestinal or bone marrow transplants where the donated organs’ immune cells recognize the recipient’s tissues as foreign and attack the recipient.

The patient underwent a procedure perfected and performed by Amy Lightner, M.D., colorectal surgeon and director of Cleveland Clinic’s Center for Regenerative Medicine and Surgery. Dr. Lightner administered three doses of mesenchymal stromal cell (MSC)-derived exosomes, a first ever, novel treatment in solid organ transplants — another first for a patient who received a full multi-organ transplant to treat PMP.

According to Dr. Vaidya, “The patient’s recovery was absolutely amazing. His symptoms abated within two hours of the first dose.”

Nine months post-transplant, the patient, now 33, can eat and digest solid foods again and has energy to do what he loves, including walking and biking outdoors.

“There is currently no evidence of cancer recurrence,” said Dr. Vaidya.

 

Photo Captions: 

Header: Masato Fujiki, MD, (center) and the Cleveland Clinic surgical team, led by Anil Vaidya, MD, performing the first-in-world multi-organ transplant to treat a rare type of appendix cancer. (Photo courtesy of Cleveland Clinic)

1st insert: Anil Vaidya, M.D.

2nd insert: From left: Anil Vaidya, M.D., Shannon Jarancik, physician assistant, Amy Lightner, M.D., Andy Voge, patient, Rachel Voge, Andy’s wife, and Anita Barnoski, transplant coordinator.

Release: Cleveland Clinic / DPA media

Continue Reading

Health

Chile becomes the first country in the Americas to be verified by WHO for the elimination of leprosy  

Published

on

Santiago/Washington, D.C./Geneva, 4 March 2026 (PAHO/WHO) – The World Health Organization (WHO), together with the Pan American Health Organization (PAHO), congratulates Chile for becoming the first country in the Americas—and the second globally—to be officially verified as having eliminated leprosy disease.

Leprosy (Hansen disease) was historically recorded in Chile at the end of the 19th century on Rapa Nui (Easter Island). The disease was limited in mainland Chile, with sporadic introductions, contained through isolation and treatment measures in the Island, where the last secondary cases were managed by the late 1990s.

Since then, Chile has not reported any locally acquired case of leprosy for more than 30 years, with the last locally acquired case detected in 1993. However, the disease was never removed from the country’s public health agenda; it has remained a notifiable condition, monitored through mandatory reporting, integrated surveillance, and continuous clinical readiness across the health system.

“This landmark public health achievement is a powerful testament to what leadership, science, and solidarity can accomplish,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Chile’s elimination of leprosy sends a clear message to the world: with sustained commitment, inclusive health services, integrated public health strategies, early detection and universal access to care, we can consign ancient diseases to history.”

The verification recognizes more than three decades of sustained public health action, robust surveillance, long-term political commitment, and a health system that has remained vigilant even in the absence of local transmission.

“Chile’s achievement demonstrates that eliminating leprosy is achievable and requires building strong systems that can detect, respond to, and provide comprehensive care for people affected by the disease, including those living with chronic disabilities,” said PAHO Director Dr. Jarbas Barbosa. “Being the first country in the Americas to be confirmed as eliminating leprosy sends a powerful message to the Region—that diseases strongly linked to groups living in vulnerable conditions can be eliminated, contributing to interrupt the vicious circle between disease and poverty.”

At the request of Chile’s Ministry of Health, PAHO and WHO convened an independent expert panel in 2025 to assess whether elimination had been achieved and could be sustained over time. The panel conducted a thorough assessment, reviewing epidemiological data, surveillance mechanisms, case management protocols, and sustainability plans. Its findings confirmed the absence of local transmission and validated Chile’s capacity to detect and respond to future cases occurring among the non-autochthonous population.

“This is very good news and a source of great pride for our country. Chile has received verification of the elimination of leprosy disease, becoming the first country in the Americas and the second globally to achieve this recognition,” said Ximena Aguilera, Chile’s Minister of Health. “This milestone reflects decades of sustained public health efforts, including prevention strategies, early diagnosis, effective treatment, continuous follow-up, and the commitment of health teams across the country. It also reaffirms our responsibility to maintain active surveillance and ensure respectful, stigma-free care for all.”

Sustained training, surveillance and holistic care in a low-incidence setting

Between 2012 and 2023, Chile reported 47 cases nationwide, none of which were locally acquired.

Chile’s integrated model ensures early detection and comprehensive care: primary care centers serve as the entry point for suspected cases, with timely referrals to specialized dermatology services for diagnosis, treatment, and follow-up. Clinicians receive training aligned with WHO’s Towards zero leprosy strategy. The system prioritizes early intervention, disability prevention, and holistic care, including physiotherapy and rehabilitation services, ensuring that anyone affected by leprosy receives continuous support for both acute and long-term health needs to promote full recovery and social inclusion.

A milestone for the Region of the Americas

Chile’s accomplishment paves the way for other nations, illustrating the impact of political will, cross-sector collaboration, and adaptive planning in low-incidence settings.

Since 1995, PAHO, in coordination with WHO, has provided multidrug therapy (MDT) free of charge to countries in the Americas, including Chile. This uninterrupted access to treatment, combined with national supply systems, has been essential to curing patients, preventing disability, and interrupting transmission.

PAHO has also supported Chile in aligning surveillance with international standards, strengthening laboratory capacity, and maintaining clinical expertise in a low-incidence context, where many health professionals may never encounter a case during their careers.

Ensuring access and coverage for everyone

Chile’s elimination of leprosy has been achieved within a broader legal and social framework that protects human rights, promotes inclusion, and prevents discrimination. National legislation guarantees equal access to health care, social protection, and disability services, ensuring that people affected by leprosy receive care without stigma or exclusion.
Chile’s mixed public–private health system, with strong regulatory oversight, further strengthens equitable access, including for migrants and other vulnerable populations.

Sustaining elimination

Aligned with WHO’s Towards zero leprosy strategy and PAHO’s Disease Elimination Initiative, Chile’s experience demonstrates that elimination is not defined solely by the absence of disease, but by a sustained health system capable of detecting, responding to, and providing holistic care whenever a case appears.

Moving into the post-elimination phase, Chile is encouraged to continue reporting to WHO, maintain sensitive surveillance, and ensure that clinical expertise is retained for future sporadic cases as well as any cases acquired outside the country. The verification panel also recommended formally designating a referral centre and leveraging WHO Academy’s online training for health workers and staff, strengthening long-term capacity and preparedness.

Continue Reading

Health

TCI Hospital Celebrates Successful “Heart Strong TCI” Initiative During Heart Month

Published

on

(Providenciales – Monday, March 2, 2026) TCI Hospital proudly announces the successful achievement of its Heart Strong TCI initiative, a comprehensive Heart Month campaign focused on raising awareness and strengthening cardiovascular disease prevention efforts across the Turks and Caicos Islands.

Heart disease remains the leading cause of death in the Turks and Caicos Islands, highlighting the critical need for sustained public education, risk-factor reduction, and early intervention. The Heart Strong TCI initiative was designed to actively engage the community through education, outreach, and physical activity.

Key Activities Included:

Educational Training Sessions

Healthcare professionals conducted structured sessions addressing hypertension, diabetes, cholesterol management, nutrition, exercise, smoking cessation, and the early warning signs of heart disease.

House Call Talk Show Feature

A dedicated Heart Month episode of the hospital’s House Call program provided expert discussion on cardiovascular risk factors and prevention strategies, empowering viewers with practical, evidence-based guidance.

Red Fridays Awareness Campaign

Throughout the month, staff wore red every Friday to increase visibility around heart disease awareness and reinforce the campaign’s message within the community.

Heart Strong 5K Walk/Run

In collaboration with the Rotary Club, TCI Hospital hosted a community-wide 5K walk/run to promote physical activity as a cornerstone of heart health. The walk/run also provided an opportunity for community screening.

Digital Health Education Campaign

To expand its reach, TCI Hospital also shared ongoing heart health education tips and prevention messages across its social media platforms, including Facebook, LinkedIn, and Instagram. These posts provided actionable guidance on diet, exercise, blood pressure control, and lifestyle modification, and encouraging community members to learn CPR.

Heart Strong TCI: A Continuous Commitment

While Heart Month has officially ended, Heart Strong TCI represents an ongoing institutional commitment to cardiovascular disease prevention and awareness. TCI Hospital will continue to prioritize:

  • Community-based education initiatives
  • Preventative screening and early detection programs
  • Lifestyle and wellness promotion
  • Strategic partnerships that advance public health outcomes

“Heart Strong TCI is not limited to a single month,” CEO, Dr. Denise Braithwaite-Tennant.  “Cardiovascular disease prevention requires sustained effort. We remain committed to promoting healthy hearts across the Turks and Caicos Islands year-round.”

For more information about cardiovascular health services or upcoming screening initiatives, please contact TCI Hospital at 649-941-2800 in Providenciales, 649-941-2900 in Grand Turk or email us at info@interhealthcanada.tc

About TCI Hospital

TCI Hospital is dedicated to delivering high-quality healthcare services to the people of the Turks and Caicos Islands, with a strong emphasis on prevention, education, and community wellness.

Continue Reading

Health

What to Look for with Self-Checks at Home

Published

on

February is National Self- Check Month and family medicine physician at Cleveland Clinic, OH, John Hanicak, MD, highlights why at home self-checks are extremely important when it comes to not just early cancer detection but identifying other illnesses too and offers tips on what to look out for.

“Sometimes Ilook at them as sort of like your check engine light on the car, just like therewould be a red flashing light that tells you that there’s something wrong with acar and prompts you to bring that in and get serviced. Your body does the samething. It gives you warning signs tolook intothat symptom a little bit further,” said Hanicak.

Dr. Hanicak saidself-checks are going to be a little different for everyone. 

However, in general, he recommends looking for anything that may seem abnormal, such asunexplained weight loss,blood in your urine, bumps and bruisesthat won’t heal,and changes in bowel habits. 

For example, if you suddenly start going to the bathroom a lot more than you used to, that could bea signof something more serious. 

He also suggestsdoing regular skin checksanddocumentingany molesor spotsthat start to look different. 

“Realize that you are your own person.There’s nobody else in the world exactly like you.You’ve got your own set ofideas, your own family history and your own genetics.Know what is normal for you, and when that changes, that’s the kind of thing thatwe would be interested in talking about,” said Dr. Hanicak. 

Dr. Hanicaknotes that self-checks are not meant to replace cancer screenings, as those are just as important to keep up with. 

Press Release: Cleveland Clinic

Continue Reading

FIND US ON FACEBOOK

TRENDING